Central and peripheral anti-hyperalgesic effects of diosmin in a neuropathic pain model in rats.

Biomed Pharmacother

Laboratorio No. 7 "Dolor y Analgesia", Departamento de Farmacobiología, Cinvestav-Sede Sur. Calz. de los Tenorios No. 235, Col. Granjas Coapa, Mexico, D.F., 14330, Mexico. Electronic address:

Published: January 2018

Flavonoids are natural compounds showing anti-hyperalgesic activity in models of pain. Diosmin is a compound poorly studied in the treatment of neuropathic pain. This study evaluates the anti-hyperalgesic actions of diosmin and possible mechanisms of action involved by using a neuropathic pain model in rats. Experimental neuropathic pain was induced by chronic constriction injury (CCI) in male Wistar rats, then aesthesiometric index and plantar tests were assessed to evaluate mechanical and thermal hyperalgesia, respectively, in order to explore the analgesic effects of acute and sub-chronic treatment with diosmin. The GABA, 5-HT, D-like and opioid receptors participation, as well as levels of TNF-α, IL-1β and IL-6, were evaluated in the spinal cord and sciatic nerve tissues after acute and subchronic diosmin administration. In addition, the presence of diosmin on cerebral samples was determined by UHPLC-MS analysis. Acute and sub-chronic treatment with diosmin significantly diminished the mechanical and thermal hyperalgesia induced by CCI in rats. This anti-hyperalgesic effects of diosmin were modified in the presence of naloxone (1mg/kg, i.p.) and haloperidol (0.1mg/kg, i.p.), but not by GABA and 5-HT receptor antagonists. The anti-hyperalgesic effects of diosmin were also linked with reduced levels of TNF-α, IL-1β and IL-6. The presence of diosmin in the cerebral samples was confirmed by chromatographic analysis. In conclusion, our results provide evidence that diosmin produces significant anti-hyperalgesic effects acting at central level by an opioid and D dopaminergic receptors participation, and at peripheral level by reducing proinflammatory cytokines.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopha.2017.10.077DOI Listing

Publication Analysis

Top Keywords

anti-hyperalgesic effects
16
neuropathic pain
16
effects diosmin
12
diosmin
11
pain model
8
model rats
8
mechanical thermal
8
thermal hyperalgesia
8
acute sub-chronic
8
sub-chronic treatment
8

Similar Publications

N-Palmitoylethanolamide enhances antinociceptive effect of tramadol in neuropathic rats.

Biomed Pharmacother

January 2025

Laboratory 7, "Pain and Analgesia", Department of Pharmacobiology, Center for Research and Advanced Studies (CINVESTAV), Sede Sur, Mexico City, Mexico.

The efficacy of opioids in the treatment of chronic pain is limited; however, the adverse effects they produce are considerable. N-palmitoylethanolamide (PEA), a bioactive lipid mediator with structural similarities to endocannabinoids, has exhibited notable anti-inflammatory and analgesic effects in preclinical models. The objective of this study was to investigate the antinociceptive properties, motor coordination (MC), and constipation effects of tramadol and PEA in combination within a neuropathic pain model.

View Article and Find Full Text PDF

Opioid use disorder is a public health problem that includes symptoms such as withdrawal syndrome and opioid-induced hyperalgesia. Currently, drugs to treat side effects of opioids also have undesirable effects, which lead to limitations. This study investigated the effect of a treatment with cannabidiol in morphine-induced hyperalgesia and withdrawal behavior in morphine-dependent rats.

View Article and Find Full Text PDF

Neuropathic pain, one of the most refractory pain diseases, remains a formidable medical challenge. There is still an unmet demand for effective and safe therapies to address this condition. Herein, a rat model of nerve injury-induced neuropathic pain is first established to explore its pathophysiological characteristics.

View Article and Find Full Text PDF

Unlabelled: Glucagon-like peptide 1 (GLP-1) receptor agonists are frequently used to treat type 2 diabetes and obesity. Despite the development of several drugs for neuropathic pain management, their poor efficacy, tolerance, addiction potential, and side effects limit their usage. Teneligliptin, a DPP-4 inhibitor, has been shown to reduce spinal astrocyte activation and neuropathic pain caused by partial sciatic nerve transection.

View Article and Find Full Text PDF
Article Synopsis
  • Melatonin shows a therapeutic effect for treating migraines, but how it works at the receptor level was previously unclear.
  • In this study, researchers used rat models and various antagonists to analyze how melatonin affects pain behaviors, CGRP levels, and mast cell activation related to migraine conditions.
  • The findings indicate that melatonin reduces migraine symptoms by modulating CGRP expression and mast cell activation, primarily through the MT2 receptor, while its effects are not reversed by the MT3 antagonist prazosin.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!